Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes
Authors' conclusion
In this ITC versus semaglutide 2.4 mg, tirzepatide 10 and 15 mg were associated with statistically significant greater weight, BMI and HbA1c reduction and tirzepatide 15 mg with statistically significant improvements in multiple cardiometabolic risk factors crucial in managing obesity or overweight among patients with T2D. Both tirzepatide doses also had a generally similar safety profile to semaglutide.
Study context
- Population
- Participants with T2D and body mass index (BMI) ≥ 27 kg/m², ≥1 unsuccessful prior dietary weight reduction effort and haemoglobin A1c (HbA1c) 7%-10% on stable therapy2 trials
- Comparison
- Tirzepatide 10 and 15 mg QW vs semaglutide 2.4 mg QW
Methodological detailsBucher indirect treatment comparison (ITC) via placebo, heterogeneity assessment
- Bucher ITC via placebo
- Heterogeneity assessment
Primary result
As reported in the abstract
Weight, BMI and HbA1c
- Tirzepatide 10 and 15 mg: statistically significant greater reductions in weight, BMI and HbA1c vs semaglutide
Further findings
≥5% and ≥15% weight reduction
- Tirzepatide 15 mg: statistically significant greater odds vs semaglutide
Cardiometabolic risk factors (waist circumference, FPG, TG)
- Tirzepatide 15 mg: statistically significant improvements vs semaglutide
HDL, LDL, systolic and diastolic blood pressure
- Both tirzepatide doses: non-significant trends of greater improvements vs semaglutide
Original publication
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes. Diabetes Obes Metab. Published 19 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →